Methods of cancer treatment using an atr inhibitor
AssigneeVertex Pharmaceuticals Incorporated
InventorsMarina S. PENNEY, John Robert POLLARD, Darin TAKEMOTO, David GEHO, James SULLIVAN, Philip Michael REAPER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of identifying a cancer having sensitivity to an ATR inhibitor compound, and treating subjects with such identified cancers with the ATR inhibitor, particularly in combination with a DNA damaging agent.
Claims33
A method of treating a patient having cancer, comprising administering to a patient with a cancer identified as having a reduced cyclin dependent kinase inhibitor 1A (CDKN1A) activity as compared to CDKN1A activity in control tissue or cell a therapeutically effective amount of an ATR inhibitor to sensitize the cancer to a DNA damaging agent.
7-16. (canceled)
21-37. (canceled)
39-47. (canceled)
(canceled)
A method of treating a patient having a cancer, comprising:
- measuring the level of cyclin dependent kinase inhibitor 1A (CDKN1A) activity in a cancer of a patient;
- comparing the measured CDKN1A activity to CDKN1A activity in a control tissue or cell;
- and
- (a) treating the patient with a cancer treatment regimen which does not include treatment with an ATR inhibitor in combination with a DNA damaging agent if the cancer is identified as having a CDKN1A activity which is substantially similar to CDKN1A activity in control tissue or cell;
- and
- (b) treating the patient with a cancer treatment regimen which includes treatment with an ATR inhibitor in combination with a DNA damaging agent if the cancer is identified as having a CDKN1A activity which is reduced as compared to CDKN1A activity in control tissue or cell.
(canceled)
Dependencies are inferred from the claim text.